Active Ingredient History

  • Now
Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
hr3 | immunoglobulin g1, anti-(humanized mouse monoclonal hr3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hr3 kappa-chain, dimer | nimotuzumab | theracim-hr3 | theraloc | theraloc theracim


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue